The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-04-30

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recent studies have demonstrated that PPARγ as well as diet control could improve glycemic control, decrease serum ALT level, decrease hepatic fat distribution, and increase intrahepatic insulin sensitivity. The purposes of this study are:

1\. Primary aims:

1. Comparison between Pioglitazone and placebo groups in terms of steatosis and liver function tests.
2. Evaluation of clinical safety of Pioglitazone

2\. Secondary aims:

1. Comparison between Pioglitazone and placebo groups in terms of liver necroinflammation and fibrosis.
2. The impact of Pioglitazone on the related metabolic index, including insulin resistance(HOMA-IR), newly-onset diabetes, metabolic syndrome, lipid profiles (T-Chol, HDL-C, LDL-C, TG).
3. Comparison between Pioglitazone and placebo groups in terms of high-sensitive C-reactive protein changes.

3\. Interventional aim: Assessment the association between magnetic resonance imaging study and intrahepatic fat distribution before and after Pioglitazone treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)

NCT00994682

Nonalcoholic Steatohepatitis Nonalcoholic Fatty Liver Disease Type 2 Diabetes Mellitus

COMPLETED PHASE4

Treatment of Nonalcoholic Steatohepatitis With Pioglitazone

NCT00013598

Fatty Liver Nonalcoholic Steatohepatitis

COMPLETED PHASE2

A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD

NCT02285205

Type 2 Diabetes Non-alcoholic Fatty Liver Disease

COMPLETED PHASE4

Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)

NCT00681733

Metabolic Parameters and Liver Histology

UNKNOWN NA

Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

NCT05842512

Nonalcoholic Steatohepatitis (NASH)

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pioglitazone belongs to thiazolidinediones and anti-diabetes drug which decreases the insulin resistance. It increases the use of glucose of peripheral tissues and decrease the production of glucose from liver and dose not influence the production of insulin. It is agonist of peroxisome proliferator-activated receptor-gamma (PPARγ) and by binding to the receptors of PPARγ in various tissues it has effects on transcription of the insulin-dependent gene. In animal model, pioglitazone has shown to influence the metabolism by the insulin-dependent mechanism.

Recent studies have demonstrated that PPARγ as well as diet control could improve glycemic control, decrease serum ALT level, decrease hepatic fat distribution, and increase intrahepatic insulin sensitivity. Meanwhile, PPARγ could also prevent the development of alcohol-induced steatohepatitis, improve hepatic necroinflammatory activity, and decrease lipid deposition. It is not yet clearly known how the effect of P-PARγ agonist among Asian peoples.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pioglitazone

Pioglitazone 30 mg/day for 6 months and 3 months of follow-up period after treatment

Group Type EXPERIMENTAL

Pioglitazone

Intervention Type DRUG

1. Name: GLITOS（Pioglitazone）
2. Dosage form: Tablets
3. Dose(s): 30mg
4. Dosing schedule: QD
5. Duration: 6 months

Placebo

Placebo 30 mg/day for 6 months and 3 months of follow-up period after treatment

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

placebo 30 mg/d for 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pioglitazone

1. Name: GLITOS（Pioglitazone）
2. Dosage form: Tablets
3. Dose(s): 30mg
4. Dosing schedule: QD
5. Duration: 6 months

Intervention Type DRUG

placebo

placebo 30 mg/d for 6 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

GLITOS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female patients with 18-70 years of age
2. Liver biopsy findings consistent with the diagnosis of NASH with or without compensated cirrhosis within one year before baseline
3. Compensated liver disease
4. Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
5. All fertile males and females must be using two forms of effective contraception during treatment during the 3 months after treatment.
6. ALT level between 1.3-5 x ULN for 2 occasions during 6 months before screening.
7. HbA1C ≦ 8.0 during screening

Exclusion Criteria

1. Therapy with any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) \*6 months before baseline.
2. History or other evidence of a medical condition associated with chronic liver disease other than NASH (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, \> 20 g/day for female or \> 40 g/day for male, toxin exposures)
3. hepatocellular carcinoma
4. History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
5. Serum creatinine level \>1.5 times the upper limit of normal at screening and calculated creatinine clearance as calculated by Cockcroft and Gault \< 60mL/min during screening
6. History of ischemic heart disease during screening
7. New York Heart Association (NYHA) Functional Class 1-4 cardiac status during screening
8. Albumin \<3.2g/dL during screening
9. Total bilirubin \>1.2 x ULN during screening. Patients with history of asymptomatic indirect hyperbilirubinemia whose total bilirubin \< 2 x ULN and direct bilirubin \< 20% of total bilirubin could be included.
10. History of prothrombin time \> 15 seconds or International normalized ratio (INR) \> 1.3
11. Organ, stem cell, or bone marrow transplant
12. History of serious concurrent medical illness that in the investigator's opinion might interfere with therapy this includes significant systemic illnesses (other than liver disease) such as chronic pancreatitis
13. Active systemic autoimmune disorder
14. Pregnancy (or lactation) or, in subjects capable of bearing children, inability / unwillingness to practice adequate contraception
15. Females of child-bearing potential (post-puberty) unwilling or unable to have pregnancy testing at any study visit
16. Therapy with a systemic antiviral agent (with the exception of prophylaxis or treatment of influenza or chronic HSV) within the past 30 days prior to screening.
17. Concurrent participation in another clinical trial in which the subject is or will be exposed to another investigational or a non-investigational drug or device within 6 weeks of the screening visit
18. Current therapy with insulin within 1 week prior to screening.
19. Experienced use with PPARg agonist (e.g., rosiglitazone, pioglitazone) within 6 months prior to screening.
20. Known hypersensitivity to any component of PPARg agonists
21. A history of hepatotoxicity to TZDs and/or a history of severe edema or a medically serious fluid-related event associated with the use of TZDs
22. History of metformin use within 3 months prior to screening.
23. Type Ⅰ diabetes
24. Seropositive of HBsAg, anti-HCV or anti-HIV during screening or 3 month prior to screening.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No